Is ESPR or HIMS more undervalued in 2026?

CirclFi compares Esperion Therapeutics, Inc. (ESPR) and Hims & Hers Health, Inc. (HIMS) using 13 institutional-grade valuation models. ESPR has a Quality of Company score of 5.2/10 while HIMS scores 6.7/10.

Which is a better buy — ESPR or HIMS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ESPR and HIMS valuations compare?

ESPR at $3.13 and HIMS at $25.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ESPR vs HIMS Valuation Comparison 2026 — Intrinsic Value Analysis

ESPR

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

LOW

Price

$3.13

Last close

Models

8/13

Active

HIMS

Drug Manufacturers - Specialty & Generic

Hims & Hers Health, Inc.

Quality

6.7

out of 10

Value Trap

LOW

Price

$25.38

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ESPR Fair Value	ESPR Upside	HIMS Fair Value	HIMS Upside
Bayesian DCF	Intrinsic	$1.09	-65.0%	$14.62	-42.4%
Earnings Power Value	Intrinsic	—	—	$3.51	-87.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$2.33	-25.7%	$22.52	-11.3%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ESPR vs HIMS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ESPR vs HIMS — Which Stock Is More Undervalued?

HIMS scores higher with a 6.7/10 quality rating vs ESPR's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Esperion Therapeutics, Inc. (ESPR) and Hims & Hers Health, Inc. (HIMS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ESPR currently trades at $3.13 with a QOC of 5.2/10, while HIMS trades at $25.38 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).